Analytical Characterization of Monoclonal Antibodies with Novel Fc Receptor-Based Chromatography Technique by Chakrabarti, Atis et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books








of Monoclonal Antibodies 
with Novel Fc Receptor-Based 
Chromatography Technique
Atis Chakrabarti, Jukka Kervinen, Egbert Müller, 
Toru Tanaka and Kazuaki Muranaka
Abstract
Most clinically approved large biotherapeutics are monoclonal antibodies (mAbs), 
primarily belonging to immunoglobulin G subclass-1 (IgG1) and, to a lesser extent, 
IgG2 and IgG4. Glycosylation is the main source of post-translational heterogeneity of 
mAbs, impacting their drug therapeutic mechanism of action (MOA). Glycosylation 
is also one of the critical factors in drug product solubility, kinetics, stability and 
efficacy. Thus, monitoring glycan critical quality attributes (CQAs) is an essential part 
of any biopharmaceutical development. The binding affinity of an IgG to its cellular Fc 
receptor (FcR) depends on both its IgG subclass and Fc domain glycosylation pattern. 
Since composition of the N-glycans also correlates to the Antibody-Dependent Cellular 
Cytotoxicity (ADCC), the glycosylation pattern needs to be monitored for consis-
tency in potency and efficacy. This applies for the original mAb biologics as well as 
biosimilars. In this chapter, we present a truly novel way to assess the variances in mAb 
glycoforms using FcγRIIIa-based affinity chromatography. First, a brief overview of the 
Fc receptor function is presented. Then, the principle of FcR-based affinity chromatog-
raphy is explained including how this column’s potential to analyze a variety of mAbs 
according to their N-glycan content is highly selective and robust. Finally, we provide 
examples of the FcR column’s potential to improve analytical characterization of mAbs 
with practical applications such as effective cell line screening, monitoring of glycoengi-
neering, process development and process control in manufacturing.
Keywords: FcR, glycoform, N-glycan, monoclonal antibody, mAb, biosimilar, 
affinity chromatography, antibody-dependent cellular cytotoxicity, ADCC
1. Introduction
Affinity chromatography is a popular method for the purification of biomol-
ecules. The purification involves interaction of the biomolecule with a ligand 
covalently immobilized to a solid stationary phase. Elution occurs as a function of 
binding strength of the biomolecule to the stationary phase, tighter the binding 
later the elution time in a linear gradient. Due to high selectivity and fast separa-
tion, affinity chromatography is regarded as the most widely used purification 
method for capture step in biopharmaceutical industry. Different types of affinity 
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chromatography ligands are available as resins and pre-packed columns for purifi-
cation at various scales. Similarly, different types of U/HPLC affinity chromatogra-
phy columns are available for analytical characterization and quality control. This 
chapter focuses on a recently introduced novel FcR-based affinity column, TSKgel-
FcR-IIIA-NPR, that enables chromatographic characterization of mAbs based on 
their N-glycan content attached to a highly conserved Asn-297 in Fc region.
2. Brief overview of Fc receptor
A brief overview of the Fc Receptor (FcR) structure and function is provided to 
best understand the chromatography principle of the column discussed in this chap-
ter. FcR proteins belong to immunoglobulin (Ig) superfamily [1]. Interest in FcRs for 
biotherapeutic research has gained momentum since 1980s. The purification of FcR 
from the glycoprotein fraction of the placental membranes by chromatography was 
reported in 1982 [2]. A functional 40 kDa FcR, with low affinity for native IgG, was 
purified from the human peripheral nerve extract using F(ab)2 fragments of mAb 
against placental FcR as affinity agent in 1989 [3]. Important role of FcR in IgG dis-
tribution to the brain [4], inhibition of cell activation [5] and in enhancement and 
suppression of the effector function [6] have also been reported. Overall, it became 
evident that FcRs are important for numerous biological functions.
2.1 FcγRs
The FcRs binding to immunoglobulin G (IgG) are known as Fc-gamma recep-
tors (FcγR). FcγRs play essential role in immunity, inflammatory and infectious 
diseases [7]. Immune enhancement and suppression are influenced by binding to 
these FcγRs [6]. Additional interaction between hyaluronic acid (HA) and sialic 
acids on immune cells helps to optimize the FcR-mediated effector function [8]. Fcγ 
 receptors do not bind to IgA or IgM [9].
2.2 Fcγ receptor binding to IgG
Typical IgG is Y-shaped protein of ~150 kDa in size, containing two heavy chains 
and two light chains (Figure 1). The heavy chain (HC) contains three constant 
domains (CH1–CH3) and a variable domain (VH) with three complementarity-
determining regions (CDRs). The light chain (LC) has only one constant domain 
(CL) and a variable domain (VL) with CDRs. The Fd consists of VH and CH1. LC 
and Fd together form the antigen binding fragment (Fab). The CH2 domain of each 
heavy chain of IgG has a highly conservative asparagine (N) residue at position 297 
(Asn297 or N297) that is almost invariably glycosylated. Fcγ receptor binding site 
is located near the hinge region of IgG, close to N297 in the CH2 domain. The most 
flexible portion of the hinge region is between CH1 and CH2 domains of a heavy 
chain. The four chains are covalently connected via disulfide bridges [10]. Fraction 
crystallizable (Fc) is composed of CH2 and CH3 domains of the two heavy chains. 
The highly conserved glycan moiety at position N297 infers structural changes to 
the Fc-region required for binding to FcγR. Subtle differences in the glycan compo-
sition at this site, thus, can affect the conformational rigidity of the Fc-structure, 
and may also alter the interaction with FcγR by direct contact [11].
2.3 FcγR subclasses
FcγRs are divided into three subclasses, abbreviated as FcγRI, FcγRII and FcγRIII. 
Extracellular regions of all the FcγRs are extremely homologous, whereas the 
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cytoplasmic domains differ considerably from each other [12]. FcγRI exhibits the high-
est affinity for IgG, Ka 10
8–109 M−1 whereas FcγRII and FcγRIII show a weaker affinity 
[13] for monomeric IgG, Ka ≤ 10
7 M−1. Receptor clustering is essential for FcγR signal-
ing. FcγRIII (also known as CD16) is a cluster of differentiation molecule found on the 
surface of natural killer (NK) cells, neutrophils, monocytes and macrophages.
2.4 FcγRIII isoforms
FcγRIII exists in two different isoforms, (a) FcγRIIIa or CD16a and (b) FcγRIIIb 
or CD16b. Both forms take part in intracellular signal transduction. Two nearly 
identical genes in human encode these two isoforms. FcγRIIIa is a 50–65 kDa type-1 
transmembrane protein whereas FcγRIIIb is a 48 kDa glycosylphosphatidylino-
sitol (GPI)-anchored protein. This chapter focuses on the modified recombinant 
FcγRIIIa protein ligand, immobilized on a polymethacrylate stationary phase and 
packed into an analytical chromatography column that can be used for characteriza-
tion of antibodies based on their N-glycan content on Asn297.
2.5 FcγRIIIa and glycosylation mode of IgG
Post-translational modifications, particularly glycosylation, of both IgG 
antibodies and Fcγ receptors modulate the affinity of their interaction. N-glycan 
(Figure 2) is a well-defined complex biantennary structure composed of a core 
hepta-saccharide, made up of N-acetylglucosamine (GlcNAc) and mannose, 
followed by variable additions of galactose, sialic acid (N-acetylneuraminic acid), 
fucose, and bisecting GlcNAc residues [11].
The attached glycans play various crucial roles on the function of immunoglobu-
lins. Fc sialylation prolongs serum half-life of therapeutic antibodies [14]. Figure 3  
shows details of the structure of the glycosylated Fc fragment complexed to a 
FcγRIIIa receptor [15]. In non-fucosylated mAb, the carbohydrate-carbohydrate 
interactions increase binding affinity between N-Glycan of IgG-Fc and N-Glycan of 
FcR (KD = 7.2 × 10
−9 M) while in fucosylated mAb the carbohydrate-carbohydrate 
interaction is weekened or non-existent depending on the extent of steric hindrance 
of the fucose moiety (KD = 3.0 × 10
−7 M) [15].
Figure 1. 




The glycosylation of Fc part is prerequisite for its affinity to FcR. Therapeutic 
monoclonal antibodies recognize specific cell surface-expressed antigens in 
malfunctioning cells (e.g. cancer cells) and elicit immune effector functions such 
as Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) (Figure 4). Glycan 
composition at conserved N297 in IgG largely affects the binding affinity, thus 
regulating ADCC activity.
FcγRIIIa protein contacts Fc portion of IgG (to both CH2 regions) and to 
attached glycans. The glycans from FcγRIIIa side are also apparently in contact 
with glycans from IgG-Fc. The binding is asymmetrical in nature as revealed from 
the co-crystal structure of Fc-FcγRIII complex [16], although the stoichiometry 
of binding is 1:1. Lack of fucosylation in core Fc-glycan dramatically increases the 
ADCC activity due to enhanced binding affinity of FcγRIIIa to IgG [17].
Figure 2. 
A schematic representation of a common N-glycan structure where blue squares denote to GlcNAc, 
green circles denote to mannose, yellow circles denote to galactose, purple diamonds denote to sialic acid 
(N-acetylneuraminic acid) and red triangle denote to fucose (reprinted with permission).
Figure 3. 
Crystal structure of glycosylated Fc-FcγRIIIa complex. (A) Top and side views of the structure of the 
glycosylated Fc-FcγRIIIa complex. The Fc chains are shown in blue and magenta and the receptor in cyan. The 
oligosaccharides are depicted as ball-and-stick representation. (B) View on the interaction interface between 
afucosylated Fc fragment and glycosylated Fc receptor. Chain A of the Fc fragment is shown in blue, the Fc 
receptor in cyan. Hydrogen bonds are presented as dashed lines with distance between donor and acceptor 
atoms. (C) View on the interaction interface between fucosylated Fc fragment and glycosylated Fc receptor. 
Chain A of the Fc fragment is shown in magenta, the Fc receptor in dark violet. Core fucose of fucosylated Fc is 
highlighted in yellow [15]. (Reprinted with permission).
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3. TSKgel FcR-IIIA-NPR affinity column
TSKgel FcR-IIIA-NPR affinity column contains non-porous polymethacrylate 
base beads as stationary phase. The ligand is a modified recombinant non-glyco-
sylated FcγRIIIa of 20 kDa, produced in E. coli expression system. Recombinant 
FcγRIIIa ligand has eight amino acid substitutions as compared to its wild-type form. 
These changes were necessary for stabilization of the ligand structure [18]. The 2.7 Å 
crystal structure of recombinant FcγRIIIa protein verifies the molecular basis of the 
IgG-FcR complex formation. No significant difference was found between the crystal 
structures of glycosylated wild-type FcγRIIIa expressed in human embryonic kidney 
(HEK) cells vs. non-glycosylated recombinant FcγRIIIa from E. coli (Figure 5). This 
confirms suitability of E. coli-produced non-glycosylated FcγRIIIa to be used as an 
affinity ligand in a chromatography resin. Notably, no direct contact of the terminal 
Asn297 N-glycan galactose of IgG and modified non-glycosylated FcγRIIIa was 
observed [19]. Both proteins were crystallized as complex with Fc [19].
The dimension of the TSKgel FcR-IIIA-NPR column is 4.6 mm ID × 7.5 cm (l) 
with a total bed volume of 1.25 mL. Polymethacrylate-based matrix is composed of 
non-porous material with ~5 μm particle size. Maximum pressure limit of the column 
is 90 bar (9 MPa). The column is suitable for both HPLC and UHPLC instrument 
settings. The recommended run temperature is 15–25°C. The operational pH range 
is from pH 4 to 8. In general, most monoclonal antibodies bind effectively on the 
column at pH 6.5. Typically, 50 mM ammonium citrate (or ammonium acetate) 
buffer is used. A linear pH gradient from pH 6.5 to 4.5 over 16 column volumes (CV) 
at the flow rate of 1.0 mL/min is recommended. Figure 6 shows a typical three-
peak chromatographic profile for a monoclonal antibody in these settings. Sodium 
chloride can be added to buffer to enhance the separation if needed. Longer retention 
time indicates stronger mAb affinity to the ligand. However, as to the general compo-
sition of glycans, it should be noted that all the three peaks still contain a mixture of 
glycoforms with variable amounts of galactose and other sugar molecules (Figure 7).
From a related experiment (Figure 7), the three peaks were collected for glycan 
analysis and ADCC activity assay. Determination of the glycan structures revealed 
that the retention time increase correlates with increased number of the terminal 
galactose. Terminal galactose tends to stabilize conformation of the Fc region, 
providing tighter binding onto FcγRIIIa affinity ligand [20]. However, FcR column 
is not designed for quantitation of only galactose but to obtain a more general 
understanding of the variation in distribution of the glycan content among the 
Figure 4. 
Schematic representation of the antibody-Fc receptor interaction resulting in ADCC activity.
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three peaks. Although added galactose increases retention time, other factors (as 
explained below) also affect the mAb binding affinity.
The results shown in the Figure 7 support the binding model presented for 
galactose in the Figure 8. The crystal structure, basis of a cartoon model in the 
Figure 8, surprisingly did not show direct contact of the galactose units with 
the receptor that could more easily explain galactose effect on the affinity for 
FcγRIIIa. Instead, based on the evidence reported in literature so far, it has been 
proposed that the galactose moiety can influence the dynamic and conforma-
tional assembly of IgG-Fc. Hydrogen-deuterium exchange mass spectrometry 
Figure 6. 
A typical 3-peak elution profile for a monoclonal antibody using a TSKgel FcR-IIIA-NPR column with 
correlation to ADCC activity.
Figure 5. 
Crystal structures of a recombinant non-glycosylated FcR ligand (Panel a) and a glycosylated native form 
(Panel b) (reprinted with permission).
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Figure 7. 
Correlation between the number of galactose units and retention time [20] (reprinted with permission).
Figure 8. 




(HDX-MS) study using purified IgG glycovariants support this hypothesis. By the 
deuterium exchange mass spectrometry, it was noticed that the deuterium uptake 
increases in the peptide ranging from 245 P to 256 T in the following order: Peak 
1 > Peak 2 > Peak 3. This result implicates that this particular peptide exhibits a 
more rigid conformation as the fraction of galactose units increase. Differential 
Scanning Calorimetry (DSC) experiment also proved that the peak 3 contains 
antibodies with the highest galactose content, and it exhibited the greatest dena-
turation enthalpy. This result thus suggests that the terminal galactose engages 
in non-covalent interaction with surrounding residues leading to increased 
conformational stability. The value of entropy change decreased as the content of 
galactose increased, suggesting a reduction of the conformational entropy of the 
antibody. More specifically, terminal galactose moiety seems to especially stabi-
lize the mAb hinge region. In N-glycans containing galactose, the CH2 domain 
remains in more rigid conformation as compared to the agalactosylated (G0F) 
glycoform (i.e. no galactose). Overall, the number of terminal galactoses have the 
greatest impact on the binding affinity of mAb onto the column [19]. However, 
the other types of glycans such as fucose, mannose and sialic acid also affect the 
binding.
4. Correlation between mAb retention time and ADCC activity
In order to confirm correlation with ADCC activity and retention time, 
Rituximab as an example [20], was analyzed and three successive peaks from 
TSKgel FcR-IIIA-NPR column were collected. ADCC bioassay was performed for 
these peaks using the Promega ADCC reporter assay kit (Figure 9). In the assay, 
higher luminescence (RLU units), as compared to mAb concentration, denotes 
to stronger ADCC activity. As a measure of ADCC potency, EC50 values (mAb 
concentration with 50% of the maximal ADCC activity) were determined. RLU 
units for Rituximab sample prior to load and for three fractions were plotted as 
a function of their concentrations (μg/mL) (Figure 9, Panel B). The order of 
ADCC activity in the peaks is as follows: peak 3 > peak 2 > mAb > peak 1. The 
result thus clearly indicates that the peak 3 has the highest ADCC activity as 
compared to the other two peaks. This study proves that the increased retention 
Figure 9. 
ADCC reporter bioassays for Rituximab and its glycoforms separated on TSKgel FcR-IIIA-NPR. Panel A: A 
typical 3-peak elution pattern for the mAb. Panel B: ADCC reporter bioassay for the mAb control and collected 
peaks from panel A. Panel C: EC50 values for the three peaks. (reprinted with permission).
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time for the peaks obtained from the U/HPLC assay indeed correlates with the 
higher ADCC activity.
The core fucose can also exert a strong modulatory effect on the affinity for 
FcγRIIIa. Figure 10 illustrates the location of a fucose molecule in the glycan moi-
ety. In the mAb, the core fucose inhibits the carbohydrate contacts and decreases 
the binding affinity. Fucosylation of N-glycan thus reduces the affinity of mAb-FcR 
interaction by steric hindrance within the Fc cavity, obstructing the carbohydrate–
carbohydrate interaction [15].
Afucosylated mAb binds effectively to FcγRIIIa ligand [19]. Subsequently, 
fucosylated and non-fucosylated mAbs were compared on the column where it was 
shown that deletion of core fucose significantly increased both retention time and 
the ADCC activity (Figure 11).
Sialic acid (N-acetylneuraminic acid) has a role in ADCC activity. Sialylation 
in the context of core fucosylation significantly decreased ADCC activity [21] 
as the sialic acid lowers the binding affinity to Fc receptor [19]. In absense of 
core fucosylation, sialylation doesn’t have any significant impact on ADCC 
 activity [21]. FcγRIIIa affinity chromatography yields longer retention by core 
fucosylation, terminal galactosylation and sialylation [18]. Overall, the effect 
Figure 10. 
Schematic representation of the core fucose location in the N-glycan moiety (reprinted with permission).
Figure 11. 
Effect of the core fucose on ADCC activity [20] (reprinted with permission).
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of different glycan molecules on the binding strength to Fc receptor can be 
arranged in the following order: Galactosylated (terminal) > Afucosylated > 
Sialylated (terminal) N-glycans in mAb. Similalry, retention time and ADCC 
activity is expected to be in the following order in the other forms of glyco-
sylation patterns; A2G2 > A2G2S2 > A2G0, High mannose (HM) > FA2G2 and 
FA2G2S2 unless otherwise affected by any other factor. High mannose and 
A2G0 may be of similar activity. Complement-dependent cytotoxicity (CDC) is 
not significantly related to sugar structure [18].
5. Glycosylation profiling of a variety of monoclonal antibodies
IgG1 is the most abundant antibody in human body. Other antibodies are IgG2, 
IgG3, and IgG4 (Figure 12). Generally, IgG1, IgG3, and to some extent, IgG4 are 
formed against protein antigens. IgG2 is the major subclass formed against repeti-
tive T cell-independent polysaccharide structures found on encapsulated bacteria 
[22]. Most of the biotherapeutics predominantly belong to IgG1 subclass. The 
antibodies from subclasses other than IgG1, as well as numerous engineered forms, 
are also gaining plenty of interest for use as biotherapeutics (Figure 12).
Several commercially available IgGs were recently analyzed in-house using 
TSKgel FcR-IIIA-NPR column to compare their elution profiles. Almost all IgGs 
yielded the typical 3-peak separation profile although there was substantial dif-
ference in each peak height between IgGs. Generally, IgG1, IgG3 and IgG4 sub-
classes bind to TSKgel FcR-IIIA-NPR whereas IgG2 does not have affinity. Due to 
Figure 12. 
A structural representation of the IgG subclasses and the variation within these subclasses, including 
allotypes, hinge variation, and glycosylation. The variation originating from allotypic polymorphisms in the 
immunoglobulin heavy gamma (IGHG) Fc domain is indicated with blue stars. Except for the star representing 
the variation in hinge length between IgG3 allotypes, each smaller blue star indicates amino acid variation at 
one particular residue in the constant domain. Glycans attached to N297 in Fc region are highly variable and the 
frequency of each glycan moiety on IgG antibodies in human serum is indicated [22] (reprinted with permission).
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individual peak size differences, each mAb is indicative of its unique separation 
profile (Figure 13). This study thus shows that TSKgel FcR-IIIA-NPR column can be 
used for the analysis of a variety of IgG subclasses for glycosylation profiling. The 
results typically well correlate to ADCC activity.
Since the first FDA approvals of biosimilars in the USA in 2015, the interest 
continues to increase toward biosimilars. They are, in general, less costly to develop 
than the original or innovators. However, the biosimilar manufacturers are required 
to confirm the extent of similarity with the corresponding innovator. In the recent lit-
erature report [23], it was indeed confirmed that glycan microheterogeneity may play 
a critical role in effector function between the originals and biosimilars. In the study, 
it was shown that a biosimilar had a higher level of afucosylated glycans, resulting in 
a stronger FcγRIIIa binding affinity and increased ADCC activity. The study in the 
Figure 14 also shows that the TSKgel FcR-IIIA-NPR column yielded dissimilar chro-
matographic pattern for biosimilars as compared to its innovator. Thus this column 
can be used for monitoring biosimilar consistent with the innovator biomolecule.
Figure 14. 
Comparison of Roche’s innovator Rituximab to its two biosimilar biotherapeutic forms. The figure also includes 
mogamulizumab (Poteligeo™) as an example of a completely afucosylated mAb.
Figure 13. 
Analysis of a variety of monoclonal antibodies on TSKgel FcR-IIIA-NPR.
Monoclonal Antibodies
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6. Factors affecting the chromatographic separation
6.1 Salt concentration
Salts affect the separation of mAb on TSKgel FcR-IIIA-NPR. To best control 
the pH in the linear gradient, mobile phase should consist of a buffer with suitable 
buffering capacity whereas neutral salts are used to increase the ionic strength. Both 
components affect the binding affinity. Buffer provides pH control and salt ions 
provide charge shielding or stoichiometric ion bonding on the stationary phase and 
mAbs. Salts impart specific or non-specific effects by modulating protein–protein 
and protein-surface interactions. Binding affinity to the column depends on the 
binding constant. Increasing salt concentration have shown to lead to the elution 
at earlier retention time (Figure 15, Panel A), although the intensity of the effect 
probably is also related to the individual mAb studied. The binding strength is also 
dependent on the buffer used such as sodium citrate or sodium acetate. Citrate 
yielded stronger binding and hence higher retention time. Acetate buffer instead 
yielded better resolution of the peaks as compared to citrate (Figure 15, Panel B).
In the affinity chromatography, the optimum flow rate of elution may be depen-
dent on the molecule-specific interaction with the ligand. Irrespective of the flow 
rates (Figure 16), all the three glycoform peaks eluted within 67% of mobile phase 
B when the analysis was carried out using a linear gradient of 50 mM sodium citrate 
buffer from pH 6.5 to 4.5 over 50 minutes at 20°C. Although flow rate did not have 
effect on elution pH, lower flow rate may be used to increase the sensitivity due to 
longer residence time in the flow cell.
Figure 16. 
Increased sensitivity at lower flow rate.
Figure 15. 
Effect of salt (Panel A) and buffer (Panel B) on the separation of mAb glycoforms.
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6.2 Gradient slope
The gradient elution method is common for the separation of species of differ-
ent binding strength. Figure 17 shows the effect of a gradient slope on the separa-
tion mAb on TSKgel FcR-IIIA-NPR. As expected, longer gradient time increased the 
resolution between the peaks whereas the overall peak area and relative ratio of the 
peak areas remained unchanged. Figure 17 indicates how shallower slope increased 
the resolution between the three peaks. This is particularly noticeable between 
peaks 2 and 3. On the other hand, it should be noted that, for any further analytical 
Figure 17. 
Effect of gradient slope on the separation efficiency of peaks.
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work (e.g. for mass spec), longer gradient increases the peak volumes and thus peak 
fractions will be more diluted.
6.3 Temperature
The ligand in FcR-IIIA-NPR column is a 20-kDa folded polypeptide and thus spe-
cial care is to be considered to maintain protein conformation intact with proper run 
temperature. Figure 18 shows the separation of mAb at four different temperatures 
(5°C, 15°C, 20°C, 25°C) at flow rate of 0.2 mL/min. As the temperature increased, 
the retention time of the three peaks decreased, indicating somewhat lower binding 
affinity as a function of higher temperature. However, importantly, overall peak 
profile at each temperature remains unchanged. Thus, for practical reasons, tem-
perature range from 15 to 25°C is recommended for most analytical work. Following 
the completion of the analysis the column needs to be stored at 2–8°C.
6.4 Sample load
Figure 19 shows the effect of load amount of mAb on the separation profile. 
The limit of detection was determined as 1.5 μg as per USP definition S/N of 2–3. A 
load of 3.16 μg could still be easily quantified (LOQ ). The analysis was repeatable, 
robust and the total peak area increased proportionately as the load amount was 
Figure 18. 
Effect of temperature on the separation of mAb.
Figure 19. 
Effect of sample load on the separation of mAb.
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increased in a linear manner in consecutive injections. Relative ratio of the indi-
vidual peak areas in the three peaks remained constant. The column can generally 
be used up to 100 μg protein load. However, 5–50 μg load of mAb is recommended 
for the best resolution and for maintaining the lifetime of the column.
Presence of aggregates in IgG samples impact the binding to the Fcγ receptors. A 
recently published article reports that deamidated IgG samples caused aggregation or 
formation of higher molecular weight (HMW) species and thereby impacted the bind-
ing affinity. Asparagine deamidation led to reduced binding of IgG to the low affinity 
FcγRIIIa receptor [24]. IgGs may also be more prone to aggregation when glycans are 
absent, which in turn has an effect on Fc effector functions. Lack of glycan and its effect 
on binding is explained below in Section 7.1. IgG dimers and aggregates may also bind 
stronger to different types of Fc receptors and thus have significant impact on affinity 
determination. Accumulated strength of multiple non-covalent affinities between the 
ligand and the receptor is known as avidity effect. This effect can alter the binding to 
the receptor and should be considered during the analysis mAb with dimer and higher 
order aggregates. The interaction, if any, needs to be evaluated in case-by-case basis. 
Up to 5% of aggregates in IgG samples changed the binding and kinetics to each of the 
Fc receptors [24]. Methionine is easily oxidized to methionine sulfoxide which can also 
lead to light chain aggregation. Oxidation has impact on the binding to the Fcγ receptors 
and depends on the extent of oxidation. As reported [24], methionine oxidation below 
7% did not impact on binding to the receptors. Taken together, all above factors should 
be considered when using this column, especially during analysis method development 
for mAbs containing any amount of aggregates or oxidized forms.
7. Robustness of TSKgel FcR-IIIA-NPR affinity column
7.1 Selectivity
The usefulness of any affinity chromatography column depends on several 
robustness factors. Here, selectivity is dependent on the nature of N-glycan. This is 
clearly demonstrated by analyzing enzymatically deglycosylated mAb. PNGase-F 
deglycosidase reacts between asparagine residue and the innermost N-acetyl glucos-
amine (GlcNAc) of the complex oligosaccharide or high mannose content. Figure 20 
shows that enzymatically deglycosylated NIST mAb does not bind to the column and 
thus elutes in void volume.
7.2 Lot-to-lot variability
Scope of quality control of the therapeutic antibodies is expanding rapidly due to 
the emergence of biosimilars, “biobetter” forms and numerous other kinds of biolog-
ics in the biotherapeutic market. Lot-to-lot difference in the activity of innovator 
mAb may vary up to 20% in the manufacturing process [25]. Although substantial 
improvement has been attained in CHO cell engineering during recent years, and 
different strategies are there e.g., to produce afucosylated antibody drugs, still not 
enough technology is available to fully control in vivo glycosylation during production 
[26]. The lot-to-lot difference in N-glycan content may give rise to a wide variety of 
risk and thus N-glycan heterogeneity is a key factor to be monitored in quality control.
To demonstrate importance of the mAb lot-to-lot quality control, two manu-
facturing lots of mAb were analyzed using the TSKgel FcR-IIIA-NPR column 
(Figure 21). Both lots yielded a similar 3-peak elution profile. However, when 
percentual peak areas of the individual peaks were compared to check the consis-
tency between the two mAb lots. Lot B showed a higher glycan percentage in peak 
Monoclonal Antibodies
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1 (42% versus 34%) and lower percentual amounts in peaks 2 and 3. In a subse-
quent ADCC assay, this also correlated with lower ADCC activity in the lot B. This 
experiment thus supports the notion that FcR affinity chromatography is suitable 
for lot-to-lot quality control of therapeutic mAbs.
To confirm consistency in FcR column manufacturing is also equally important 
for quality control. Three different lots of TSKgel FcR-IIIA-NPR column (Lots A, B, 
and C) were tested using reference mAb sample under identical chromatographic 
conditions (Figure 22). No significant variation in 3-peak profile was noticed 
between the three different column lots.
7.3 Effect of host cell proteins on the separation of mAb
Most mAb pharmaceuticals are produced in CHO cell culture system. Host 
cell proteins (HCPs), or host cell impurities, are collectively recognized as several 
forms of host cell products such as DNA, proteins, endotoxin and, if contaminated, 
viruses. These together are considered as process-related contaminants. They often 
have antigenic or pyrogenic effects in human and thus must be removed during 
downstream processing.
Figure 21. 
N-glycan analysis of two manufacturing lots of a therapeutic antibody on TSKgel FcR-IIIA-NPR.
Figure 20. 
Deglycosylated mAb does not bind to the column.
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With regard to QC characterization, it is also necessary to assess if host cell 
proteins can interfere mAb binding on a TSKgel FcR-IIIA-NPR column. In the 
following study, CHO cell culture supernatant (“feedstock”) was directly used for 
FcR column analysis and the results were compared to a previously purified mAb 
in the same assay (Figure 23, Panel a). However, no significant difference was 
noticed between the two profiles. This indicates that the HCPs had no significant 
impact on the mAb affinity to FcR column and about 5 μg of mAb in a feedstock 
was enough to obtain a suitable signal for monitoring process development in a 
bioreactor. The robustness of the assay was further tested using the mAb in CHO 
cell supernatant with 200 consecutive injections (Figure 23, Panel b). The total 
peak area remained constant with a % RSD (n = 10) of 0.79. It was also noticed 
that addition of NaCl to minimize unwanted non-specific interactions further 
improved durability at 20°C. The Figure 23 (Panel c) shows how FcR column can 
be used for cell line selection and upstream monitoring. In this case, samples from 
CHO cell culture supernatant were collected, filtered, captured on protein A, 
and then injected to a TSKgel FcR-IIIA-NPR column. NaCl was added to improve 
separation. Glycoform changes in mAb were monitored over 14 days. The propor-
tion of the intensities and peak areas of the three peaks significantly changed 
over the days that can be correlated to indicate changes in ADCC activity during 
Figure 23. 
(a) Analysis of CHO cell feedstock containing mAb versus purified mAb. (b) Assessment of FcR column 
stability over 200 injections. (c) Monitoring of glycan composition changes during fermentation.
Figure 22. 
Lot-to-lot consistency in TSKgel FcR-IIIA-NPR column manufacturing.
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fermentation. Thus, by monitoring samples from the bioreactor using TSKgel 
FcR-IIIA-NPR, process engineers can approximate the optimal day for desired 
yield and ADCC activity.
7.4 Column pH stability and cleaning
Recommended working pH for the FcR column as mentioned in operational 
conditions and specifications (OCS) is from pH 8 to 4. As mentioned earlier, the 
protein ligand contains eight amino acid substitutions for improved stability. To 
further test acid stability, the column was held at pH3 for 200 hours. The modified 
ligand did not lose its binding affinity and the selectivity while the wild-type lost 
the binding affinity and selectivity within one hour (Figure 24). Based on this and 
other studies, a pH range of 3–8 is can be used for short term and pH 4.5–7 for long 
term usage. Due to a protein nature of the ligand, acetonitrile and other organic 
solvents are not suitable for the column. For cleaning, 3–5 injections of 0.5–2 mL 
of a buffer containing 500 mM NaCl or 20% ethanol can safely be used in reverse 
direction at half the normal flow rate. Once the cleaning procedure is complete, 
it is necessary to equilibrate the column in mobile phase for at least 45 minutes. 
Cleaning with alkalic solutions above pH 8 are not recommended since this will 
denature the protein ligand. Sodium azide (0.05%) can be used in the mobile phase 
as  antibacterial agent.
8.  Mass spectrometric characterization of glycoform peaks separated by 
TSKgel FcR-IIIA-NPR column
Mass spectrometric characterization is becoming an integral part of the liquid 
chromatography analysis. As an example how TSKgel FcR-IIIA-NPR column can be 
utilized in mass spec work, we describe here an in-line LC–MS intact mAb analysis 
of trastuzumab (Herceptin Biosimilar). The analysis was carried out using 100 mM 
volatile ammonium acetate buffer and a linear pH gradient from pH 6.5 to pH 4.5 at 
the flow rate of 0.4 mL/min. The wavelenght of detection was 280 nm. The column 
temperature during the analysis was maintained at 20°C. Three glycoform peaks could 
be detected by UV detector. Mass spectrometric detection was carried out using SCIEX 
X500B Q-TOF in ESI positive mode, within mass/charge (m/z) range of 5000–7000. 
Ion source gases 1 and 2 were maintained at 50 psi, curtain gas at 30 psi, CAD gas at 
7 psi and temperature at 450°C. Spray voltage was maintained at 5200 V, declustering 
Figure 24. 
Acid stability of a recombinant FcγRIII ligand as compared to a wild type ligand.
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potential at 275 V, and collison energy at 20 V. Time bins to sum was set at 120. For the 
automated characterization of the data acquired on the X500B QTOF, SCIEX Biotool 
kit software was used. Total Ion Chromatogram (TIC) was obtained by summing up 
intensities of all mass spectral peaks belonging to the same scan. An overlay of UV pro-
file and TIC profile is shown in Figure 25. For further analysis of glyosylation profiles 
of these three peaks, SCIEX BioPharmaView™ software can be used.
As mentioned earlier, organic solvents such as acetonitrile are not suitable for the 
column and vapor pressure of water is very low. Thus, volatile salts such as 100 mM 
ammonium acetate or ammonium formate are used. To avoid ion source contamination 
during prolonged use, molarity should be kept at low (preferably <50 mM). Depending 
on the need for further optimization for different mAbs, volatile salt ammonium 
bicarbonate can also be used as such or in combination with other volatile salts.
9. Analysis of Fc fragment on TSKgel FcR-IIIA-NPR
The C-terminal part of the heavy chains contains the Fc fragment which is 
responsible for cellular effector functions, essential for proper function of most 
therapeutic mAbs. In some cases, it is desirable to express fragment antibodies that 
are smaller than intact mAbs but still are capable of eliciting their therapeutic func-
tion by activation of the immune system. Literature reports that both glycoengineer-
ing and protein engineering have rendered Fc domains with enhanced Fc receptor 
binding. In general, Fc fragments and their numerous variants are rapidly gaining 
interest as a platform in the development of efficient biotherapeutics.
The binding efficiency of the Fc fragment was tested in-house to assess suit-
ability of TSKgel FcR-IIIA-NPR column on the characterization of smaller fragment 
antibodies. In short, trastuzumab was fragmented with papain that cleaves IgG at 
His228 forming two Fab parts and one Fc part (Figure 26). The reaction mixture 
was incubated at 37°C for 15 minutes to activate papain followed by mAb addition 
and further incubation overnight at room temperature. Papain activity was stopped 
with 5 mM iodoacetamide. A control a sample (no papain during incubation) and a 
sample from papain digestion were used for this study. Size exclusion chromatogra-
phy followed by mass spectrometric analysis confirmed >95% cleavage of mAb to Fc 
and Fab fragments (data available by request).
Both the control mAb and fragments were analyzed on TSKgel FcR-IIIA-
NPR column. As expected, Fab did not bind to the FcR column but eluted in 
Figure 25. 
Overlay of UV spectrum and Total Ion Chromatogram (TIC) of Herceptin Biosimilar.
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flow-through. Fc fragment efficiently bound to the column and yielded three 
glycoform peaks similar to intact mAb (Figure 27). Same sample volumes from 
the control sample and digestion reaction mixture were loaded onto the column. 
Lower peak heights for the Fc fragment were due to loss of Fab (2 x 48 kDa) from 
the protein mass during analysis. Interestingly, slightly longer retention times were 
detected for Fc fragment peaks, thus suggesting more rigid conformational stabil-
ity for the Fc fragment leading to stronger binding as compared to the intact mAb. 
In summary, this experiment confirms that fragment antibodies, as long as they 
contain intact unobstructed Fc region, can be tested using the FcR column.
10. Novelty of TSKgel FcR-IIIA-NPR column
The mechanism of binding for IgG and other Fc engaging molecules is shown 
in the Figure 28. Complement component (C1q), Fc gamma receptors (FcγR), the 
Neonatal Fc receptor (FcRn), Tripartite motif 21 (Trim21), and Fc receptor-like 
(FcRL) molecules bind to various locations of mAb for the exertion of biological 
activity. For each ligand, the stoichiometric ratio of binding is also reported (Panel 
a). Recently, a biotinylated recombinant human FcRn immobilized to a Streptavidin 
Sepharose matrix and packed in a low pressure FPLC column has been introduced 
by Roche. A prepacked analytical protein-A affinity column (TSKgel ProteinA 
5-PW) marketed by Tosoh also interacts with Fc region. Site of interaction of FcγR 
is separate from the site of interaction for FcRn or Protein A as seen in the Figure 28 
Panel b.
Figure 26. 
Schematic representation of monoclonal antibody fragmentation with papain.
Figure 27. 
Analysis of intact mAb and Fc fragment on TSKgel FcR-IIIA-NPR column.
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TSKgel FcR-IIIA-NPR and TSKgel Protein A-5PW columns were tested for binding 
affinity of mAb with and without N-glycan using surface plasmon resonance tech-
nique (Figure 29). Protein A affinity chromatography column showed similar binding 
to mAb regardless of N-glycan whereas TSKgel FcR-IIIA-NPR column did not bind to 
mAb without N-glycan, similarly to the result in the Figure 20. Thus, the FcR column 
is unique due to its capability to analyze mAbs solely on the basis of their glycosylation.
11.  Preparative scale purification of antibodies using FcR-based 
chromatography technique
Here, we provide a quick preview of the preparative scale TSKgel FcR-IIIA-5PW 
column that will be commercially available soon. The preparative column is manu-
factured using the same recombinant FcγRIIIA protein ligand, however, the ligand 
in this column is bound to porous (~100 nm nominal pore size) polymethacrylate 
polymer base beads. The column is suited for mAb purification in a significantly 
larger scale (loading 0.5–5 mg) as compared to the analytical FcR column (loading 
≤100 μg). Chromatographic profile in the Figure 30, panel A was obtained using  
U/HPLC instrument and the analytical FcR column whereas the panel B shows peak 
separation with the preparative FcR column connected to a FPLC instrument. The 
peak separation profiles are closely similar with both columns. However, the prepar-
ative scale column allows collection of much more material for further experimenta-
tion such as glycan release, labeling and HILIC analysis, among other assays.
Figure 29. 
Selectivity of the modified recombinant FcγRIIIa ligand vs. Protein A ligand.
Figure 28. 




TSKgel FcR-IIIA-NPR affinity chromatography column is a unique tool separat-
ing monoclonal antibodies into three peaks based on their glycosylation profile. 
Selectivity of the genetically engineered FcγRIIIa ligand is very specific to the mAb 
based on its glycan composition on highly conserved Asn-297 residue. IgG1, IgG3 
and IgG4 subclasses bind to the FcR column whereas IgG2 subclass does not have 
affinity. IgA and IgM also don’t bind to this column. Non-glycosylated mAb also 
does not bind to the column. Importantly, this column can be used for fast evalu-
ation of antibody’s ADCC effector function since the peak profile correlates well 
with the ADCC activity. Longer the retention time, higher is the ADCC activity.
The generally accepted workflow for mAb characterization, based on its glycan 
content typically follows the three different pathways (Figure 31, panel A). These are 
reporter bioassay for monitoring ADCC activity, Surface Plasmon Resonance (SPR) 
for measuring FcR affinity and U/HPLC-MS analysis for characterization of the glycan 
structure. Characterization of mAb on TSKgel FcR-IIIA-NPR column can combine 
these three pathways to one workflow (Figure 31, Panel B) in most circumstances.
The column is expected to be useful in several application areas (Figure 32) 
including (a) early screening of ADCC activity, (b) upstream (cell culture) opti-
mization, (c) quality control of the mAb lot-to-lot consistency and (d) comparison 
between innovator and biosimilar products. Overall, this novel FcR affinity column 
is anticipated to be useful in research and development, characterization, manufac-
turing and quality control.
Figure 31. 
Workflow for the characterization of mAb.
Figure 30. 
Separation of mAb glycoforms using (A) analytical FcR column and (B) preparative FcR column.
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